Brief: BioCryst Begins Enrollment in Proof-of-Concept Trial of Oral Factor D Inhibitor, BCX10013
26/10/2023 12:05
Oct 26 (Reuters) - BioCryst Pharmaceuticals Inc
BCRX.O :
* BIOCRYST BEGINS ENROLLMENT IN PROOF-OF-CONCEPT TRIAL TO
CONFIRM
SAFE, EFFECTIVE, ONCE-DAILY DOSE OF ORAL FACTOR D INHIBITOR,
BCX10013
Source text for Eikon: ID:nGNXc5sy3
Further company coverage: BCRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026